Kraematon Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Kraematon Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$302K	Hold	608	–	–	0.22%	89
2026 Q1	$271K	Hold	608	–	–	0.22%	90
2025 Q4	$275K	Sell	608 -140	-19%	-$60.3K	0.22%	86
2025 Q3	$293K	Sell	748 -203	-21%	-$84.8K	0.25%	79
2025 Q2	$423K	Sell	951 -4	-0.4%	-$1.84K	0.4%	61
2025 Q1	$463K	Sell	955 -82	-8%	-$38.2K	0.47%	56
2024 Q4	$418K	Sell	1,037 -75	-7%	-$34.8K	0.41%	58
2024 Q3	$517K	Buy	1,112 +81	+8%	+$38.9K	0.51%	51
2024 Q2	$483K	Hold	1,031	–	–	0.49%	54
2024 Q1	$431K	Buy	+1,031	New	+$436K	0.43%	57
2023 Q1	–	Sell	-327	Closed	-$94.4K	–	246
2022 Q4	$94.4K	Buy	+327	New	+$99.7K	0.1%	107

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Kraematon Investment Advisors's VRTX Position: Q2 2026 in Review

Kraematon Investment Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 608 shares worth $302K. The position accounts for 0.22% of the portfolio, ranked #89.

Kraematon Investment Advisors first reported a position in VRTX in Q4 2022 and has held it in 11 quarters since. The position peaked at $517K in Q3 2024. 536 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Kraematon Investment Advisors held 608 shares of Vertex Pharmaceuticals worth $302K as of Q2 2026.
Kraematon Investment Advisors left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.22% of Kraematon Investment Advisors's portfolio in Q2 2026, its #89 holding.
Kraematon Investment Advisors first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
Kraematon Investment Advisors's Vertex Pharmaceuticals position peaked at $517K in Q3 2024.
536 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Kraematon Investment Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.